Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease
NCT05593575
Phase
Phase 2
Recruitment status
Completed
Participants
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Start date
2023-03-22
Number of sites
- Summary
- To preliminarily evaluate the efficacy and safety of the renin inhibitor (SPH3127 tablets) in reduction in proteinuria in patients with diabetic kidney disease with valsartan as the comparator, and determine the recommended dose.
- Short title
- Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease
- Official title
- A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Dose-finding Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SPH3127 Tablets in the Treatment of Diabetic Kidney Disease
- Registry reports results
- Listing at source
- Listed
- Recruitment status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Completion date
- 2024-12-31
- First posted
- 2022-10-25
- Registry last updated
- 2025-02-19
- Primary completion date
- 2024-12-31
- Start date
- 2023-03-22
- Actual participants
- Participants
- Participant count basis
- Actual
- Protocol amendments
- Number of sites
- Data monitoring committee
- Registry sponsor category
- Industry
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Source registry
- ClinicalTrials.gov
- Registry ID
- NCT05593575
- ClinicalTrials.gov ID
- NCT05593575
- Registry record
- Open registry record
- Allocation
- Randomised
- Model
- Parallel groups
- Purpose
- Treatment
- Masking
- Double masking
- Masked roles
- Participants, Investigators
Sources for study design
Percentage change from baseline in UACR
Timeframe: at the end of Week 12 of treatment
Percentage change from baseline in log-transformed UACR at the end of Week 12 of treatment
Percentage change from baseline in UACR
Timeframe: at the end of Weeks 2, 4 and 8 of treatment
Percentage change from baseline in log-transformed UACR at the end of Weeks 2, 4 and 8 of treatment
Percentage change from baseline in UPCR
Timeframe: at the end of Weeks 2, 4, 8 and 12 of treatment
Percentage change from baseline in log-transformed UPCR at the end of Weeks 2, 4, 8 and 12 of treatment
The change trend of eGFR
Timeframe: from baseline to the end of Weeks 2, 4, 8 and 12 of treatment
The change trend of eGFR from baseline to the end of Weeks 2, 4, 8 and 12 of treatment
Sources for outcomes
- Sex
- All
- Age groups
- Adults, Older adults
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Healthy volunteers
- No
- Subjects who are diagnosed with type 2 diabetes who have been treated with at least one hypoglycemic therapy within 12 months prior to screening, with basically stable blood glucose level during screening;
- During screening period, 120 mmHg ≤ sitting SBP ≤ 160 mmHg and sitting DBP < 110 mmHg;
- Laboratory results before randomization should be: 1) at least twice the result of UCAR should be 30 mg/g ≤ UACR < 3000mg/g at W-8, W-4, W-2, and W0; 2) EGFR ≥ 45mL/min/1.73 m2 at W-4 and W0; 3) AST and ALT ≤ 2 times the upper limit of normal (ULN), and total bilirubin ≤ 1.5 times ULN at W0; 4) hemoglobin ≥ 90 g/L at W0; 5) 3.5 mmol/L ≤Serum potassium ≤ 4.8 mmol/L at W-4 and W0;
- Subjects who agree to take effective contraceptive measures with their spouses throughout the study period and for up to 12 weeks after the last dose;
- Subjects who thoroughly learn about the nature, significance, possible benefits, possible inconvenience and potential risks of the trial, and understand the study procedures and voluntarily sign the informed consent form prior to their participation in the trial.
- Sitting SBP >140 mmHg and/or sitting DBP >90 mmHg at baseline (W0);
- Color ultrasonography of renal artery indicated renal artery stenosis;
- ① Acute renal insufficiency② acute nephritic syndrome, polycystic kidney, kidney stone, nephrotic syndrome; ③there is evidence that proteinuria originates from primary and secondary renal diseases other than hypertensive renal damage; ④ gross hematuria in the past one year.
- During the screening/run-in period, major modifications need to be made to the subject's corresponding treatment regimen due to poor control of other underlying diseases based on the investigator's judgement;
- Subjects with fundus lesions in malignant hypertensive, such as retinal hemorrhage and papilledema;
- Subjects who need to continuously take glucocorticoids, anti-tumor chemical or biological agents, and non-steroidal anti-inflammatory drugs during the study period;
- Subjects with a history of acute myocardial infarction, coronary artery revascularization, Class IV heart failure, acute cerebral infarction, cerebral hemorrhage and transient ischemic attack within 3 months prior to randomization;
- Subjects who have abnormal thyroid function tests with clinically significance;
- Subjects with poor control of diabetes: HbA1c ≥ 9.0% at W0;
- Subjects who have undergone major surgery within 3 months prior to screening or need to undergo major surgery during the trial;
- Subjects whose medication adherence in the run-in period is < 80% or > 120%;
- Subjects with a history of gastrointestinal surgery that may significantly change the absorption, distribution, metabolism and excretion of drugs;
- Subjects who are known to be allergic to renin inhibitors, ARBs, ACEIs and their excipients, or those with hypersensitive constitution, or those who experience serious adverse reactions;
- Women during pregnancy or lactating;
- Subjects who need transplantation before randomization and during the trial;
- Subjects with HIV infection, hepatitis B infection, hepatitis C infection, or other active infections;
- Subjects who have a history of malignant tumor, and those who are suspected of malignant tumor;
- Subjects with a past and current history of mental illness;
- Subjects with a history of drug abuse or alcohol abuse within 2 years prior to screening;
- Subjects who have participated in clinical trials of other drugs/devices as a subject within 3 months prior to screening;
- Subjects with other diseases or conditions that the investigator considers not suitable for this trial.
Sources for eligibility
- The Second Hospital of Anhui Medical UniversityHefei, China
- The 900 Hospital of the Joint Service Support Force of the People's Liberation Army of ChinaFuzhou, China
- Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhou, China
- The First Affiliated Hospital，Sun Yat sen UniversityGuangzhou, China
- The First Affiliated Hospital of Guangxi Medical UniversityNanning, China
- Guizhou Provincial People's HospitalGuiyang, China
- Harbin Medical University Affiliated Fourth HospitalHarbin, China
- Luoyang Third People's HospitalLuoyang, China
- Renmin Hospital of Wuhan UniversityWuhan, China
- The Third Hospital of WuhanWuhan, China
- The Third Xiangya Hospital of Central South UniversityChangsha, China
- The Second Norman Bethune Hospital of Jilin UniversityChangchun, China
- The First People's Hospital of YinchuanYinchuan, China
- Qinghai University Affiliated HospitalXining, China
- Xi'an Daxing HospitalXi’an, China
- Chengdu Second People's HospitalChengdu, China
- Suining Central HospitalSuining, China
- Zigong Fourth People's HospitalZigong, China
- The First Affiliated Hospital of Xinjiang Medical UniversityÜrümqi, China
- Taizhou Municipal HospitalTaizhou, China
- Beijing Tsinghua Changgeng HospitalBeijin, China
- Beijing Anzhen Hospital，Capital Medical UniversityBeijing, China
- Beijing Tiantan Hospital，Capital Medical UniversityBeijing, China
- Beijing Tongren HospitalBeijing, China
- Peking Union Medical College HospitalBeijing, China
And 20 more, listed on the interactive page.
Sources for sites
- PubMed 38682786Related publication
Sources for references
Related records
Drugs (2)
Lead sponsors (1)
Conditions (1)
- Diabetic kidney disease Primary condition